Fundraising FoxMethuselah Funds — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
OncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity.
BiotechDeep TechHealthtechSeattle, US
Matt Scholz(Executive Officer, Director)John Lewis(Executive Officer, Director)inGary Hudson(Director)in
Co-investorsHelios CapitalMethuselah FoundationChainFund CapitalInvesco
Viscient Biosciences develops drugs by studying human 3D tissue models combined with multi-omics analysis to understand disease mechanisms.
BiotechDeep TechDigital HealthSan Diego, US
Keith Murphy(Executive Officer, Director)in
Co-investorsHarmonix FundMethuselah FoundationThynk Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.